Discussing treatment choices for early cervical cell changes
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at how shared decision-making affects women's choices when they have abnormal cervical cells that may need treatment. It may help you feel more involved in choosing the right treatment for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old.
- You have been diagnosed with CIN2 or CIN3 (pre-cancerous changes in the cervix).
- You are about to have a procedure called conization (removing a cone-shaped piece of tissue from the cervix) and have not had this before.
- You are not pregnant.
- You do not have a weakened immune system (for example, from HIV or an organ transplant).
- Your abnormal cells are visible during a colposcopy, and you do not need an interpreter for your medical visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways of managing CIN 2, a moderate precancerous change on the cervix. One option is a new procedure that uses argon plasma (a type of energized gas) to treat the area; the other is careful monitoring without immediate treatment, to see if one works better at clearing the abnormal cells.
This study checks cervical “pre-cancer” and cancer early using cervical screening tests. You may benefit by getting recommended results and next steps, like treatment if something concerning is found.
This study watches to see if early precancerous cells (CIN 2 or 3) on the cervix can go away without treatment, especially in women under 40. It helps doctors understand who might avoid surgery.
This trial checks whether “therapy abstention” (not treating right away) and close monitoring is safe for certain high-grade cervical cell changes. It may help some people avoid immediate procedures while still catching any progression early.
This study tests a new tool called PreCursor-M+® to see how well it helps doctors manage CIN2, a moderate cervical cell change. It’s for people who have already been diagnosed with CIN2 and know their HPV test results.
This study compares two methods for finding early signs of cervical cancer during a routine exam. It may help doctors detect problems sooner and prevent cancer from developing.
Hear when a new CIN2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.